Stock ScreenerStock IdeasBiotech BreakthroughsBest Biotech Stocks To Buy NowTop biotech stocks that analysts expect to be profitable within the next 3 years
Stock ScreenerStock IdeasBiotech Breakthroughs
Industry: Biotechnology
Forecast Earnings Growth: Positive
| Ticker | Company | Zen Rating | Sentiment | Market Cap | Shares | Institutional % | Insider % | Net Insider (L12M) | Net Insider (L3M) |
|---|---|---|---|---|---|---|---|---|---|
| ONC | BEONE MEDICINES LTD | $39.77B | 1,438,553,263 | 1.08% | 32.05% | Net Buying | Net Selling | ||
| NVO | NOVO NORDISK A S | $219.81B | 4,465,000,000 | 5.11% | 0.00% | ||||
| KNSA | KINIKSA PHARMACEUTICALS INTERNATIONAL PLC | $3.44B | 75,795,759 | 29.76% | 9.36% | Net Selling | Net Selling | ||
| ZVRA | ZEVRA THERAPEUTICS INC | $486.97M | 56,297,535 | 42.22% | 22.75% | Net Selling | Net Selling | ||
| CORT | CORCEPT THERAPEUTICS INC | $4.19B | 105,188,217 | 25.36% | 74.64% | Net Buying | Net Buying | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | $44.12B | 132,623,144 | 69.34% | 20.94% | Net Selling | Net Selling | ||
| VCEL | VERICEL CORP | $1.89B | 50,574,026 | 82.69% | 10.15% | Net Selling | Net Selling | ||
| ARGX | ARGENX SE | $51.60B | 61,034,202 | 15.76% | 0.00% | ||||
| GMAB | GENMAB A | $18.73B | 64,238,408 | 45.77% | 0.00% | ||||
| KRYS | KRYSTAL BIOTECH INC | $8.28B | 29,232,189 | 57.26% | 25.15% | Net Selling | Net Selling | ||
| LGND | LIGAND PHARMACEUTICALS INC | $3.74B | 19,681,720 | 14.55% | 85.45% | Net Selling | Net Selling | ||
| TECH | BIO-TECHNE CORP | $9.28B | 156,453,292 | 75.07% | 2.49% | Net Buying | Net Selling | ||
| ADMA | ADMA BIOLOGICS INC | $3.81B | 237,997,765 | 72.19% | 23.68% | Net Selling | Net Selling | ||
| MNKD | MANNKIND CORP | $1.67B | 307,070,281 | 29.34% | 70.66% | Net Selling | Net Selling | ||
| ABEO | ABEONA THERAPEUTICS INC | $277.46M | 54,191,361 | 38.68% | 61.32% | Net Selling | Net Selling | ||
| HALO | HALOZYME THERAPEUTICS INC | $8.64B | 118,017,000 | 73.39% | 26.61% | Net Selling | Net Selling | ||
| RPRX | ROYALTY PHARMA PLC | $26.15B | 576,856,753 | 45.72% | 17.29% | Net Selling | Net Selling | ||
| VCYT | VERACYTE INC | $2.89B | 79,049,173 | 58.36% | 41.64% | Net Selling | Net Selling | ||
| XOMA | XOMA ROYALTY CORP | $301.53M | 12,383,103 | 10.09% | 89.91% | Net Selling | Net Buying | ||
| NAGE | NIAGEN BIOSCIENCE INC | $399.03M | 79,806,139 | 15.09% | 84.91% | Net Buying | |||
| PLX | PROTALIX BIOTHERAPEUTICS INC | $239.66M | 80,421,181 | 7.07% | 92.93% | Net Buying | Net Buying | ||
| HRMY | HARMONY BIOSCIENCES HOLDINGS INC | $2.03B | 57,596,358 | 65.29% | 25.76% | Net Selling | Net Selling | ||
| CPRX | CATALYST PHARMACEUTICALS INC | $2.99B | 122,912,387 | 64.45% | 15.89% | Net Selling | Net Selling | ||
| AUPH | AURINIA PHARMACEUTICALS INC | $1.89B | 131,840,559 | 28.60% | 12.67% | Net Buying | Net Selling | ||
| APLS | APELLIS PHARMACEUTICALS INC | $2.81B | 126,525,218 | 53.64% | 30.40% | Net Selling | Net Selling | ||
| CRMD | CORMEDIX INC | $564.92M | 78,789,045 | 43.77% | 9.68% | Net Selling | Net Selling | ||
| REGN | REGENERON PHARMACEUTICALS INC | $83.75B | 105,719,806 | 63.23% | 36.77% | Net Selling | Net Selling | ||
| UTHR | UNITED THERAPEUTICS CORP | $20.50B | 43,056,599 | 64.59% | 14.55% | Net Selling | Net Selling | ||
| BMRN | BIOMARIN PHARMACEUTICAL INC | $11.88B | 192,114,344 | 73.06% | 1.74% | Net Selling | Net Selling | ||
| ACAD | ACADIA PHARMACEUTICALS INC | $3.93B | 169,181,817 | 50.83% | 38.18% | Net Selling | Net Selling | ||
| VRTX | VERTEX PHARMACEUTICALS INC | $119.47B | 254,034,190 | 77.95% | 1.54% | Net Selling | Net Selling | ||
| INVA | INNOVIVA INC | $1.77B | 74,769,062 | 54.14% | 45.86% | Net Selling | Net Selling | ||
| EXEL | EXELIXIS INC | $11.55B | 259,708,689 | 73.35% | 5.67% | Net Selling | Net Selling | ||
| MDXG | MIMEDX GROUP INC | $773.09M | 148,102,159 | 41.99% | 58.01% | Net Buying | Net Selling | ||
| INCY | INCYTE CORP | $20.50B | 199,014,486 | 69.01% | 28.53% | Net Selling | Net Selling |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.